IBK Investment & Securities stated on November 17 that despite poor performance from its subsidiary, Dongkuk Pharmaceutical is experiencing steady growth in its cosmetics division, maintaining a buy rating and a target price of 30,000 won.
Research analyst Jeong I-soo noted, "Dongkuk Pharmaceutical's consolidated revenue for the third quarter of this year reached 258.7 billion won, a 14.0% increase compared to the same period last year." However, operating profit during the same period fell by 4.1% to 23.8 billion won.
While revenue met market expectations of 256.4 billion won, operating profit fell short of the forecast of 26.7 billion won by 10.9%.
The growth was primarily driven by the healthcare sector, which saw a 37% increase in sales to 101.5 billion won in the third quarter. Notably, cosmetics sales surged by 66% to 79.5 billion won compared to the same period last year. Consequently, the healthcare sector's share of total revenue expanded from 32.7% to 39.3%.
In contrast, the subsidiary Dongkuk Life Science reported an operating loss of 1.6 billion won due to a downturn in the diagnostic equipment market, impacting the overall profitability. Dongkuk Pharmaceutical's consolidated operating margin was 9.2%, below the standalone figure of 10.4%.
IBK Investment & Securities forecasts that consolidated revenue for the fourth quarter will increase by 13.2% year-on-year to 275 billion won, with operating profit also expected to rise by 13.2% to 27.5 billion won. Healthcare sales are projected to reach 112.5 billion won, bolstered by the expansion of overseas distribution networks and seasonal demand at year-end.
The annual healthcare export figure is anticipated to exceed 120 billion won this year. However, the extent of improvement in consolidated profits may depend on the recovery of Dongkuk Life Science's performance.
Jeong stated, "While we are adjusting short-term profit estimates downward to reflect the subsidiary's poor performance, the long-term growth visibility is increasing due to the expansion of healthcare sales centered around cosmetics, allowing us to maintain the target price of 30,000 won."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.